Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Erica Gomez"'
Autor:
Martin J. van den Bent, Peter J. Ansell, Kyle D. Holen, Maria Guseva, Andrew M. Scott, Hui K. Gan, Priya Kumthekar, David Maag, Anahita Bhathena, Erica Gomez, Xin Lu, Zheng Zha, Carolyn Mullen, Rupinder Kular, Ekaterina Pestova, Minghao Song, Irina Sokolova, Lisa Roberts-Rapp, Andrew B. Lassman
Purpose:Patients with glioblastoma (GBM) have a poor prognosis and are in desperate need of better therapies. As therapeutic decisions are increasingly guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing a potential ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15671a97fee370559bbe15233ea8d7b6
https://doi.org/10.1158/1078-0432.c.6527364.v1
https://doi.org/10.1158/1078-0432.c.6527364.v1
Autor:
Martin J. van den Bent, Peter J. Ansell, Kyle D. Holen, Maria Guseva, Andrew M. Scott, Hui K. Gan, Priya Kumthekar, David Maag, Anahita Bhathena, Erica Gomez, Xin Lu, Zheng Zha, Carolyn Mullen, Rupinder Kular, Ekaterina Pestova, Minghao Song, Irina Sokolova, Lisa Roberts-Rapp, Andrew B. Lassman
Supplementary Table S2. Concordance of FISH and WES results. Supplementary Table S3. Point mutations identified in EGFR. Supplementary Table S4. Concordance of FISH and RT-PCR results. Supplementary Table S5. Concordance of FISH and RNAseq results. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e1792b7fc7dba0544047eaf0284e3fa
https://doi.org/10.1158/1078-0432.22469823
https://doi.org/10.1158/1078-0432.22469823
Autor:
Martin J. van den Bent, Peter J. Ansell, Kyle D. Holen, Maria Guseva, Andrew M. Scott, Hui K. Gan, Priya Kumthekar, David Maag, Anahita Bhathena, Erica Gomez, Xin Lu, Zheng Zha, Carolyn Mullen, Rupinder Kular, Ekaterina Pestova, Minghao Song, Irina Sokolova, Lisa Roberts-Rapp, Andrew B. Lassman
Supplementary Table S1. Data for tumor samples and all assays performed.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45486a420e04d23f9dbed8bffb48dc5c
https://doi.org/10.1158/1078-0432.22469820.v1
https://doi.org/10.1158/1078-0432.22469820.v1
Autor:
Louis B. Nabors, David A. Reardon, John Simes, Lisa Roberts-Rapp, Ho-Jin Lee, Nicholas Butowski, Tobias Walbert, Andrew B. Lassman, Helen Wheeler, Priya Kumthekar, Andrew M. Scott, Peter Ansell, Tom Mikkelsen, Marta Penas-Prado, Kyriakos P. Papadopoulos, Martin J. van den Bent, Earle Bain, Zarnie Lwin, Erica Gomez, David Maag, Ryan Merrell, Hui K Gan, Hao Xiong, Kyle D. Holen
Publikováno v:
Cancer Chemotherapy & Pharmacology, 80(6), 1209-1217. Springer-Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff65c6833473b7cdb380bda35882ca5
Autor:
Malaka Ameratunga, Yuliya Perchyonok, Diana Cao, Andrew Mark Scott, Eddie Lau, Graeme O'Keefe, Angela Rigopoulos, Sze Ting Lee, Andrew B. Lassman, David Maag, Hui K Gan, Sagun Parakh, Aidan Seow, Ingrid Burvenich, Erica Gomez
Publikováno v:
Neuro-oncology Advances
BackgroundThe adverse impact of increasing brain tumor size on the efficacy of antibody-drug conjugates (ADCs) was investigated preclinically then validated with clinical data.Methods—Preclinical studyThe impact of tumor size on ADC tumor delivery
Autor:
Peter Ansell, Lisa Roberts-Rapp, Priya Kumthekar, Ho-Jin Lee, Marta Penas-Prado, Louis B. Nabors, David A. Reardon, Hao Xiong, Earle Bain, Erica Gomez, David Maag, Kyriakos P. Papadopoulos, Martin J. van den Bent, Tobias Walbert, Nicholas Butowski, Andrew B. Lassman, Ryan Merrell, Zarnie Lwin, Hui K Gan, Kyle D. Holen, Helen Wheeler, Andrew M. Scott, Tom Mikkelsen, John Simes
Publikováno v:
Neuro-Oncology, 21(1), 106-114. Oxford University Press
Neuro-Oncology
Neuro-Oncology
Background Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recurrent disease (rGBM). Approximately 50% of patients have tumors harboring epidermal growth factor receptor (EGFR) ampl
Autor:
Lisa Roberts-Rapp, Andrew M. Scott, Kyle D. Holen, Ekaterina Pestova, David Maag, Rupinder Kular, Maria Guseva, Martin J. van den Bent, Erica Gomez, Hui K Gan, Andrew B. Lassman, Xin Lu, Minghao Song, Zheng Zha, Carolyn Mullen, Anahita Bhathena, Peter Ansell, Sokolova Irina A, Priya Kumthekar
Publikováno v:
Clinical Cancer Research, 25(11), 3259-3265. American Association for Cancer Research Inc.
Clin Cancer Res
Clin Cancer Res
Purpose: Patients with glioblastoma (GBM) have a poor prognosis and are in desperate need of better therapies. As therapeutic decisions are increasingly guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing a potential the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38b3c9b47bba580c418ec020f665cd88
https://pure.eur.nl/en/publications/1b0ff6e9-0fa6-4c8e-8e30-2cef2a3a3eaa
https://pure.eur.nl/en/publications/1b0ff6e9-0fa6-4c8e-8e30-2cef2a3a3eaa
Autor:
Priya Kumthekar, Hao Xiong, David A. Reardon, Lisa Roberts-Rapp, Peter Ansell, Nicholas Butowski, Erica Gomez, Hui K Gan, Ryan Merrell, Lisa Fichtel, Helen Wheeler, Andrew B. Lassman, Helen Mandich, Andrew M. Scott, Ho-Jin Lee, JuDee Fischer, Wijith Munasinghe, Zarnie Lwin, Kyle D. Holen, Martin J. van den Bent
Publikováno v:
Neuro-Oncology, 20(6), 838-847. Oxford University Press
BACKGROUND: We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A). The purpose of this study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4096acfbefae3452a6b6a33fbefe9260
https://pure.eur.nl/en/publications/ec30da2b-c338-4a05-96f0-d9d40feddb11
https://pure.eur.nl/en/publications/ec30da2b-c338-4a05-96f0-d9d40feddb11
Autor:
James Lee, Peter Ansell, Andrew B. Lassman, Lisa Roberts-Rapp, Martin J. van den Bent, Kyle D. Holen, Jim Looman, Earle Bain, Christopher Ocampo, Erica Gomez
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e709ba949f05224e21038246c72ec084
https://europepmc.org/articles/PMC5693085/
https://europepmc.org/articles/PMC5693085/
Autor:
Erica Gomez, Golnaz Moazami, Maria Guseva, Christopher Ocampo, Earle Bain, Marian S. Macsai, Stella Kim
Publikováno v:
Neuro-Oncology. 20:vi15-vi16
BACKGROUND: Depatuxizumab mafodotin (depatux-m, formerly ABT-414), is an antibody-drug conjugate comprised of an EGFR-targeted antibody, a non-cleavable linker maleimidocaproyl, and the microtubule inhibitor monomethylauristatin F. Promising antitumo